Shingles vaccines comprising a TLR9 agonist
AssigneeDynavax Technologies Corporation
InventorsJohn D. Campbell, Randall N. Hyer, Robert S. Janssen, David Novack
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.
Claims24
An immunogenic composition, comprising:
- a varicella zoster virus (VZV) glycoprotein E (gE) antigen and a toll-like receptor 9 (TLR9) agonist, wherein the TLR9 agonist is an oligonucleotide of from 10 to 35 nucleotides in length comprising an unmethylated cytidine-phospho-guanosine (CpG) motif, wherein the oligonucleotide comprises the sequence of 5′-TGACTGTGAA CGTTCGAGAT GA-3′ (SEQ ID NO:1),
- wherein the immunogenic composition comprises from about 3000 μg to about 6000 μg of the oligonucleotide and from about 50 μg to about 100 μg of the gE antigen.
A kit comprising:
- i) an immunogenic composition comprising a varicella zoster virus (VZV) glycoprotein E (gE) antigen and a toll-like receptor 9 (TLR9) agonist, wherein the TLR9 agonist is an oligonucleotide of from 10 to 35 nucleotides in length comprising an unmethylated cytidine-phospho-guanosine (CpG) motif, wherein the oligonucleotide comprises the sequence of 5′-TGACTGTGAA CGTTCGAGAT GA-3′ (SEQ ID NO:1),
- wherein the immunogenic composition comprises from about 3000 μg to about 6000 μg of the oligonucleotide and from about 50 μg to about 100 μg of the gE antigen, and
- ii) instructions for administration of the immunogenic composition to stimulate an immune response against the gE antigen in a mammalian subject.
A method for stimulating an immune response against varicella zoster virus (VZV) in a mammalian subject, comprising administering to a subject in need an immunogenic composition comprising a varicella zoster virus (VZV) glycoprotein E (gE) antigen and a toll-like receptor 9 (TLR9) agonist, wherein the TLR9 agonist is an oligonucleotide of from 10 to 35 nucleotides in length comprising an unmethylated cytidine-phospho-guanosine (CpG) motif, and wherein the oligonucleotide comprises the sequence of 5′-TGACTGTGAA CGTTCGAGAT GA-3′ (SEQ ID NO:
- 1),
- wherein the immunogenic composition comprises from about 3000 μg to about 6000 μg of the oligonucleotide and from about 50 μg to about 100 μg of the gE antigen to a mammalian subject.
An immunogenic composition, comprising:
- a varicella zoster virus (VZV) glycoprotein E (gE) antigen and a toll-like receptor 9 (TLR9) agonist, wherein the TLR9 agonist is an oligonucleotide comprising the sequence of 5′-TGACTGTGAA CGTTCGAGAT GA-3′ (SEQ ID NO:1), and an aluminum salt adjuvant, wherein the immunogenic composition comprises about 6000 μg of the oligonucleotide and about 100 μg of the gE antigen.
Dependencies are inferred from the claim text.